Detalhe da pesquisa
1.
ADME properties of CHF6366, a novel bi-functional M3 muscarinic receptor antagonist and ß2 adrenoceptor agonist (MABA) radiolabelled at both functional moieties.
Xenobiotica
; 53(4): 288-308, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37376730
2.
CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
J Pharmacol Exp Ther
; 352(3): 568-78, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25576073
3.
In vitro and in vivo metabolism of CHF 6001, a selective phosphodiesterase (PDE4) inhibitor.
Xenobiotica
; 45(8): 693-710, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25733029
4.
Co-ultraPEALut in Subjective Cognitive Impairment Following SARS-CoV-2 Infection: An Exploratory Retrospective Study.
Brain Sci
; 14(3)2024 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38539680
5.
Using illusions to understand hallucinations: differences in perceptual performances on illusory figures may underscore specific visuoperceptual impairments in Parkinson's disease.
Front Neurosci
; 17: 1256224, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38125403
6.
Optimization of M3 Antagonist-PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD.
J Med Chem
; 66(16): 11476-11497, 2023 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37561958
7.
A potential protective role of magnesium in neuroCOVID
Magnes Res
; 35(1): 18-26, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36214551
8.
From the Lab to Real Life: Monitoring Cardiorespiratory Fitness during the COVID-19 Pandemic through Wearable Devices. An Exploratory Longitudinal Study on Healthy Participants.
Healthcare (Basel)
; 10(4)2022 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35455812
9.
COVID-19 lockdown: Physical activity, sedentary behaviour and sleep in Italian medicine students.
Eur J Sport Sci
; 21(10): 1459-1468, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33108970
10.
Discovery of M3 Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary Disease.
J Med Chem
; 64(13): 9100-9119, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34142835
11.
Investigation of Lung Pharmacokinetic of the Novel PDE4 Inhibitor CHF6001 in Preclinical Models: Evaluation of the PreciseInhale Technology.
J Aerosol Med Pulm Drug Deliv
; 31(1): 61-70, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28768120
12.
Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases.
J Med Chem
; 61(11): 4757-4773, 2018 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29741897
13.
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
J Med Chem
; 60(24): 10026-10046, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29200281
14.
Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
J Med Chem
; 48(18): 5705-20, 2005 Sep 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-16134939
15.
Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.
J Med Chem
; 57(3): 793-816, 2014 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24400806
16.
Single and multiple ascending dose studies of a novel tissue-selective oestrogen receptor modulator, CHF 4227, in healthy postmenopausal women.
Br J Clin Pharmacol
; 64(3): 304-16, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17367495
17.
In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents.
Pharmacol Res
; 55(4): 318-28, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17292621